Table 2 Predictors of cervical cancer screening programme period coverage in Estonia, 2009–2018
WLWH: HIV specific screening (595/2448) 24.31% | WLWH: organised screening (266/1914) 13.90% | General population women: organised screening (1210/6365) 19.01% | |||||||
|---|---|---|---|---|---|---|---|---|---|
N (% covered) | OR (95% CI) | AOR (95% CI) | N (% covered) | OR (95% CI) | AOR (95% CI) | N (% covered) | OR (95% CI) | AOR (95% CI) | |
Region | |||||||||
Capital | 1009 (31.32) | 1 | 1 | 788 (13.71) | 1 | 1 | 2618 (20.02) | 1 | 1 |
North-East | 1214 (27.76) | 0.704 (0.581,0.851) | 0.705 (0.581,0.855) | 970 (14.85) | 0.999 (0.759,1.317) | 1.007 (0.764,1.330) | 3273 (18.70) | 0.920 (0.808,1.048) | 0.918 (0.806,1.046) |
Else | 225 (27.11) | 0.662 (0.473,0.915) | 0.767 (0.544,1.071) | 156 (8.97) | 0.560 (0.298,0.978) | 0.610 (0.324,1.070) | 474 (15.61) | 0.739 (0.563,0.959) | 0.732 (0.557,0.951) |
Age groups | |||||||||
16–19 | 114 (34.21) | 1 | 1 | ||||||
20–29 | 1335 (32.96) | 0.937 (0.622,1.424) | 0.930 (0.618,1.419) | 1031 (16.39) | 1 | 1 | 3879 (18.72) | 1 | 1 |
30–39 | 563 (28.42) | 0.691 (0.448,1.078) | 0.686 (0.444,1.071) | 563 (11.19) | 0.617 (0.449,0.838) | 0.621 (0.452,0.843) | 1587 (17.77) | 0.939 (0.805,1.091) | 0.948 (0.813,1.103) |
40–49 | 222 (23.87) | 0.523 (0.315,0.868) | 0.521 (0.314,0.866) | 222 (10.36) | 0.554 (0.340,0.865) | 0.565 (0.347,0.883) | 647 (23.65) | 1.344 (1.099,1.635) | 1.364 (1.115,1.660) |
50–55 | 98 (12.25) | 0.204 (0.095,0.411) | 0.206 (0.096,0.416) | 98 (11.22) | 0.563 (0.278,1.038) | 0.586 (0.289,1.083) | 252 (19.44) | 1.047 (0.751,1.433) | 1.083 (0.776,1.484) |
56+ | 116 (8.62) | 0.136 (0.060,0.281) | 0.135 (0.060,0.281) | ||||||
Insured (uninsured if it occurs ever during the follow-up) (baseline is insured) | 1704 (34.04) 744 (18.01) | 1 0.426 (0.343,0.525) | 1 0.331 (0.264,0.412) | 1339 (15.53) 575 (10.09) | 1 0.610 (0.444,0.826) | 1 0.545 (0.394,0.745) | 6355 (19.02) 10 (10.00) | 1 0.4729 (0.026,2.520) | 1 0.477 (0.026,2.545) |
Stage at index visit (n %) | |||||||||
Clinical latency | 1955 (29.67) | 1 | 1 | 1548 (13.44) | 1 | 1 | |||
Acute | 87 (39.08) | 1.340 (0.851,2.085) | 1.444 (0.908,2.271) | 69 (23.19) | 1.794 (0.974,3.136) | 1.993 (1.073,3.523) | |||
AIDS | 382 (24.35) | 0.689 (0.531,0.887) | 0.874 (0.666,1.138) | 278 (14.03) | 1.005 (0.686,1.441) | 1.198 (0.811,1.734) | |||
Unknown | 24 (29.17) | 0.885 (0.338,2.085) | 1.069 (0.399,2.602) | 19 (15.79) | 1.178 (0.272,3.586) | 1.331 (0.304,4.131) | |||
AIDS dgn at any time of follow-up (baseline is AIDS not diagnosed) | 1383 (31.67) 483 (27.54) | 1 0.874 (0.690,1.102) | 1 0.879 (0.691,1.114) | 1066 (14.92) 400 (10.75) | 1 0.708 (0.489,1.006) | 1 0.678 (0.466,0.966) | |||
HIV care retention (yes: n %) (baseline is not retained) | 1691 (25.43) 757 (37.52) | 1 1.751 (1.453,2.108) | 1 1.972 (1.615,2.410) | 1324 (14.50) 590 (12.54) | 1 0.824 (0.614,1.095) | 1 0.939 (0.688,1.273) | |||
Drug abuse (yes: n, %) (baseline is no drug abuse) | 2088 (31.37) 360 (16.39) | 1 0.517 (0.380,0.693) | 1 0.459 (0.336,0.618) | 1624 (14.84) 290 (8.62) | 1 0.600 (0.379,0.914) | 1 0.543 (0.342,0.830) | 6360 (19.03) 5 (0.00) | 1 0 (−) | 1 0 (−) |
HCV infection (yes: n %) baseline is no HCV | 1532 (31.27) 916 (25.66) | 1 0.868 (0.718,1.048) | 1 0.754 (0.619,0.916) | 1164 (14.26) 750 (13.33) | 1 0.998 (0.759,1.307) | 1 0.844 (0.637,1.115) | 6355 (18.98) 10 (40.00) | 1 3.450 (0.845,13.217) | 1 3.500 (0.856,13.418) |
Drug abuse or HCV co-infection | 1448 (32.46) 1000 (24.40) | 1 0.780 (0.646,0.940) | 1 0.683 (0.562,0.828) | 1092 (15.11) 822 (12.28) | 1 0.856 (0.651,1.122) | 1 0.732 (0.552,0.965) | 6353 (18.98) 12 (33.33) | 1 2.703 (0.682,9.567) | 1 2.751 (0.693,9.751) |